Skip to Content
Interactive Textbook on Clinical Symptom Research Logo

Home Button

Anorexia Case Study Sections
Author Bio
Introduction
Commentator Bio
Protocol Schema
Protocol Background
Protocol Goals
Patient Eligibility
Test Schedule
Stratification Factors
Registration/Randomization
Protocol Treatment
Dosage Modification
Ancillary Treatment
Toxicity Monitoring
Treatment Evaluation
Treatment/Follow-up
Currently selected section: Ancillary Studies
Drug Information
Statistical Considerations
Pathology Considerations
Records/Data Collection Procedures
Budget
Appendices

 

Chapter 2A: Measuring Cancer Anorexia/Cachexia: Ancillary Studies
 

14.1 IL-6:

14.11 Collection of specimens - see Appendix V, Serum Specimen Logistics (not available Online).

14.12 Laboratory analysis of IL-6 levels: This will be done at Dr. Yamashita's laboratory in Japan via previously described methods (39).

14.2 Lab analysis of Neuropeptide g, Cholecystokinin, Leptin, IL-1b, and TNFa.

14.21 This will be done in Dr. George Klee's laboratory. Mayo Clinic, Rochester, MN.

14.22 One hundred (100) patients have completed a baseline, previously validated NCCTG questionnaire that includes an assessment of anorexia severity. All have also completed a concurrent blood draw. One-month clinical follow-up is available for the majority of these patients. Neuropeptide, CCK, leptin serum concentrations will be assayed in duplicate for each sample with the use of radioimmunoassay techniques. TNFa and IL-1b will be determined with an ELISA assay. The severity of each patient's anorexia will be classified as severe versus moderate based on a previously validated NCCTG anorexia scale.


Page 22 of 34